Successful, we will reply to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

MRT67307

HY-13018

(MRT 67307; MRT-67307)

MRT67307

MRT67307 Chemical Structure

MRT67307 is a dual inhibitor of the IKKe and TBK-1. IKKe and TBK-1 mediate the phosphorylation of interferon regulatory factor 3 (IRF3).

Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO $88 In-stock
5 mg $80 In-stock
10 mg $130 In-stock
50 mg $550 In-stock
100 mg $710 In-stock
200 mg Get quote
500 mg Get quote
Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO €86 In-stock
5 mg €78 In-stock
10 mg €127 In-stock
50 mg €539 In-stock
100 mg €696 In-stock
200 mg Get quote
500 mg Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: MRT67307
Cat. No.: HY-13018

MRT67307 Data Sheet

  • View current batch:

    Purity: 99.02%

  • Network Version

    DataSheet

    Pdf Version Network Version

    MSDS

    Pdf Version

    COA

    Pdf Version

    LCMS

Customer View

Related Compound Libraries

Biological Activity of MRT67307

MRT67307 is a dual inhibitor of the IKKe and TBK-1. IKKe and TBK-1 mediate the phosphorylation of interferon regulatory factor 3 (IRF3).
IC50 value:
Target: IKKe/TBK1

Protocol (Extracted from published papers and Only for reference)

More

Chemical Information

M.Wt 464.6 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C26H36N6O2
CAS No 1190378-57-4
Solvent & Solubility

in DMSO > 10 mM

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 2.1524 mL 10.7619 mL 21.5239 mL
5 mM 0.4305 mL 2.1524 mL 4.3048 mL
10 mM 0.2152 mL 1.0762 mL 2.1524 mL

References on MRT67307

[1]. Clark K et al. Novel cross-talk within the IKK family controls innate immunity. Biochem J. 2011 Feb 15;434(1):93-104.
Abstract
Members of the IKK {IκB [inhibitor of NF-κB (nuclear factor κB)] kinase} family play a central role in innate immunity by inducing NF-κB- and IRF [IFN (interferon) regulatory factor]-dependent gene transcription programmes required for the production of pro-inflammatory cytokines and IFNs. However, the molecular mechanisms that activate these protein kinases and their complement of physiological substrates remain poorly defined. Using MRT67307, a novel inhibitor of IKK?/TBK1 (TANK {TRAF [TNF (tumour-necrosis-factor)-receptor-associated factor]-associated NF-κB activator}-binding kinase 1) and BI605906, a novel inhibitor of IKKβ, we demonstrate that two different signalling pathways participate in the activation of the IKK-related protein kinases by ligands that activate the IL-1 (interleukin-1), TLR (Toll-like receptor) 3 and TLR4 receptors. One signalling pathway is mediated by the canonical IKKs, which directly phosphorylate and activate IKK? and TBK1, whereas the second pathway appears to culminate in the autocatalytic activation of the IKK-related kinases. In contrast, the TNFα-induced activation of the IKK-related kinases is mediated solely by the canonical IKKs. In turn, the IKK-related kinases phosphorylate the catalytic subunits of the canonical IKKs and their regulatory subunit NEMO (NF-κB essential modulator), which is associated with reduced IKKα/β activity and NF-κB-dependent gene transcription. We also show that the canonical IKKs and the IKK-related kinases not only have unique physiological substrates, such as IκBα, p105, RelA (IKKα and IKKβ) and IRF3 (IKK? and TBK1), but also have several substrates in common, including the catalytic and regulatory (NEMO and TANK) subunits of the IKKs themselves. Taken together, our studies reveal that the canonical IKKs and the IKK-related kinases regulate each other by an intricate network involving phosphorylation of their catalytic and regulatory (NEMO and TANK) subunits to balance their activities during innate immunity.

Inhibitor Kit

Related IKK Products

  • Amlexanox

    Amlexanox (AA673; CHX3673) is a specific inhibitor of IKK(epsilon) and TBK1; inhibition of IKK(epsilon) and TBK1 activity as determined by MBP phosphorylation showing an IC50 of approximately 1–2 (mu)M.

  • AZD3264

    AZD 3264 is an IkB-kinase IKK2 Inhibitor, IKK2 has been identified as one of the novel pathways to treat inflammatory conditions such as asthma, chronic pulmonary obstructive disorder (COPD) and rheumatoid arthritis.

  • BAY 11-7082

    BAY 11-7082 is an irreversible inhibitor of IKK(alpha) and phosphorylation of cytokine-inducible I(kappa)B(alpha) (nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-(alpha), NFKBIA; IC50=10 (mu)M).

  • BI605906

    BI605906, a novel inhibitor of IKK(beta), inhibits IKK(beta) with an IC50 value of 380 nM when assayed at 0.1 mM ATP.

  • IKK 16

    IKK 16 is a selective I(kappa)B kinase (IKK) inhibitor for IKK-2, IKK complex and IKK-1 with IC50 of 40 nM, 70 nM and 200 nM, respectively.

  • IKKε-IN-1

    IKK(epsilon)-IN-1 is a potent IKK(epsilon) inhibitor; inhibit the in-situ ΙKΚ (epsilon)-mediated phosphorylation of IRF3 with an IC50 value of less than about 100 nM.

  • IKK-2 inhibitor VIII

    IKK-2 inhibitor VIII is a potent and selective IKK-2 inhibitor with IC50 of 8.5 nM.

  • IKK-3 Inhibitor

    IKK-3 Inhibitor is a potent, selective, inhibitor of IKK-epsilon kinase with IC50 of 40 nM; inactive at IKK-(alpha) and IKK-(beta).

  • IMD-0354

    IMD-0354 is a synthetic selective NF-kB inhibitor.

  • MLN120B

    MLN120B is a potent and effective IKKbeta inhibitor.

MORE